comparemela.com
Home
Live Updates
Patt Highlights Payer, Education Considerations in Trastuzumab Deruxtecan Use for HER2-Low Breast Cancer : comparemela.com
Patt Highlights Payer, Education Considerations in Trastuzumab Deruxtecan Use for HER2-Low Breast Cancer
At Patient-Centered Oncology Care®, Debra Patt, MD, PhD, MBA, of Texas Oncology, discussed managed care considerations that arise from the groundbreaking DESTINY-Breast04 study presented earlier this year.
Related Keywords
Tennessee ,
United States ,
Texas ,
American ,
Caffreym Trastuzumab ,
Debra Patt ,
Astrazeneca ,
College Of American Pathologists ,
American Society Of Clinical Oncology ,
American Society ,
Clinical Oncology ,
Texas Oncology ,
Patient Centered Oncology Care ,
American Journal ,
American Pathologists ,
Breast Cancer ,
Destiny Breast04 ,
Trastuzumab Deruxtecan ,
Her2 Low ,
comparemela.com © 2020. All Rights Reserved.